Moreover, 4.7 times higher possibility to achieve pCR was observed in patients with HER2 IHC 3+ breast cancer than in patients with HER2 IHC 2+ breast cancer (OR = 4.726, 95%CI: 2.706–8.253, p < 0.001). Here, ERBB2 is linked to breast carcinoma.